 | • レポートコード：D0GIR-00978 • 出版社/出版日：GlobalInfoResearch / 2020年9月18日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、血管免疫芽球性T細胞リンパ腫（AILT）治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。血管免疫芽球性T細胞リンパ腫（AILT）治療の種類別市場規模（化学療法、放射線療法、その他）、用途別市場規模（病院、クリニック、外来手術センター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Roche、Eisai Co., Ltd.、Merck、Novartis、Takeda Pharmaceutical、Seattle Genetics、Genmab AS、Bristol-Myers Squibb、Cellerant Therapeutics ・地域別グローバル市場分析 2015年-2020年 ・血管免疫芽球性T細胞リンパ腫（AILT）治療の北米市場（アメリカ、カナダ、メキシコ） ・血管免疫芽球性T細胞リンパ腫（AILT）治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・血管免疫芽球性T細胞リンパ腫（AILT）治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・血管免疫芽球性T細胞リンパ腫（AILT）治療の南米市場（ブラジル、アルゼンチン） ・血管免疫芽球性T細胞リンパ腫（AILT）治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：化学療法、放射線療法、その他 ・用途別分析：病院、クリニック、外来手術センター、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment sales will be xx in 2020 from Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market has been segmented into:
Chemotherapy
Radiation Therapy
Others
By Application, Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment has been segmented into:
Hospitals
Clinics
Ambulatory Surgical Centers
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market.
The report offers in-depth assessment of the growth and other aspects of the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share Analysis
Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment sales, revenue and market share for each player covered in this report.
The major players covered in Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment are:
Roche
Eisai Co., Ltd.
Merck
Novartis
Takeda Pharmaceutical
Seattle Genetics
Genmab AS
Bristol-Myers Squibb
Cellerant Therapeutics
Among other players domestic and global, Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Overview
1.1 Product Overview and Scope of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment
1.2 Classification of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment by Therapy
1.2.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Therapy in 2019
1.2.3 Chemotherapy
1.2.4 Radiation Therapy
1.2.5 Others
1.3 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market by End Users
1.3.1 Overview: Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market by Regions
1.4.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Industry Impact
1.5.1 COVID-19 Potential Implications for the Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Roche SWOT Analysis
2.1.4 Roche Product and Services
2.1.5 Roche Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Eisai Co., Ltd.
2.2.1 Eisai Co., Ltd. Details
2.2.2 Eisai Co., Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Eisai Co., Ltd. SWOT Analysis
2.2.4 Eisai Co., Ltd. Product and Services
2.2.5 Eisai Co., Ltd. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Merck SWOT Analysis
2.3.4 Merck Product and Services
2.3.5 Merck Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Novartis SWOT Analysis
2.4.4 Novartis Product and Services
2.4.5 Novartis Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Takeda Pharmaceutical
2.5.1 Takeda Pharmaceutical Details
2.5.2 Takeda Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Takeda Pharmaceutical SWOT Analysis
2.5.4 Takeda Pharmaceutical Product and Services
2.5.5 Takeda Pharmaceutical Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 Seattle Genetics
2.6.1 Seattle Genetics Details
2.6.2 Seattle Genetics Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Seattle Genetics SWOT Analysis
2.6.4 Seattle Genetics Product and Services
2.6.5 Seattle Genetics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Genmab AS
2.7.1 Genmab AS Details
2.7.2 Genmab AS Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Genmab AS SWOT Analysis
2.7.4 Genmab AS Product and Services
2.7.5 Genmab AS Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 Bristol-Myers Squibb
2.8.1 Bristol-Myers Squibb Details
2.8.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Bristol-Myers Squibb SWOT Analysis
2.8.4 Bristol-Myers Squibb Product and Services
2.8.5 Bristol-Myers Squibb Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 Cellerant Therapeutics
2.9.1 Cellerant Therapeutics Details
2.9.2 Cellerant Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Cellerant Therapeutics SWOT Analysis
2.9.4 Cellerant Therapeutics Product and Services
2.9.5 Cellerant Therapeutics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players Market Share
3.2.2 Top 10 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Market Share by Regions
4.2 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
5 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Countries
5.1 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Countries (2015-2020)
5.2 USA Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
6 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Countries
6.1 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Countries (2015-2020)
6.2 Germany Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
6.4 France Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Countries
7.1 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Countries (2015-2020)
7.2 China Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
7.5 India Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
8 South America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Countries
8.1 South America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Countries (2015-2020)
8.2 Brazil Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment by Countries
9.1 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Market Share by Therapy (2015-2020)
10.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Forecast by Therapy (2019-2024)
10.3 Chemotherapy Revenue Growth Rate (2015-2025)
10.4 Radiation Therapy Revenue Growth Rate (2015-2025)
10.5 Others Revenue Growth Rate (2015-2025)
11 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Segment by End Users
11.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by End Users (2015-2020)
11.2 Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Forecast by End Users (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Ambulatory Surgical Centers Revenue Growth (2015-2020)
11.6 Others Revenue Growth (2015-2020)
12 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Forecast (2021-2025)
12.1 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size Forecast (2021-2025)
12.2 Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Forecast by Regions (2021-2025)
12.3 North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Forecast (2021-2025)
12.6 South America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Roche Corporate Information, Location and Competitors
Table 7. Roche Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Major Business
Table 8. Roche Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Total Revenue (USD Million) (2017-2018)
Table 9. Roche SWOT Analysis
Table 10. Roche Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product and Solutions
Table 11. Roche Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Eisai Co., Ltd. Corporate Information, Location and Competitors
Table 13. Eisai Co., Ltd. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Major Business
Table 14. Eisai Co., Ltd. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Total Revenue (USD Million) (2018-2019)
Table 15. Eisai Co., Ltd. SWOT Analysis
Table 16. Eisai Co., Ltd. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product and Solutions
Table 17. Eisai Co., Ltd. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Merck Corporate Information, Location and Competitors
Table 19. Merck Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Major Business
Table 20. Merck Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Total Revenue (USD Million) (2017-2018)
Table 21. Merck SWOT Analysis
Table 22. Merck Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product and Solutions
Table 23. Merck Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Novartis Corporate Information, Location and Competitors
Table 25. Novartis Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Major Business
Table 26. Novartis Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Total Revenue (USD Million) (2017-2018)
Table 27. Novartis SWOT Analysis
Table 28. Novartis Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product and Solutions
Table 29. Novartis Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Takeda Pharmaceutical Corporate Information, Location and Competitors
Table 31. Takeda Pharmaceutical Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Major Business
Table 32. Takeda Pharmaceutical Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Total Revenue (USD Million) (2017-2018)
Table 33. Takeda Pharmaceutical SWOT Analysis
Table 34. Takeda Pharmaceutical Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product and Solutions
Table 35. Takeda Pharmaceutical Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Seattle Genetics Corporate Information, Location and Competitors
Table 37. Seattle Genetics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Major Business
Table 38. Seattle Genetics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Total Revenue (USD Million) (2017-2018)
Table 39. Seattle Genetics SWOT Analysis
Table 40. Seattle Genetics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product and Solutions
Table 41. Seattle Genetics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Genmab AS Corporate Information, Location and Competitors
Table 43. Genmab AS Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Major Business
Table 44. Genmab AS Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Total Revenue (USD Million) (2017-2018)
Table 45. Genmab AS SWOT Analysis
Table 46. Genmab AS Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product and Solutions
Table 47. Genmab AS Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 49. Bristol-Myers Squibb Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Major Business
Table 50. Bristol-Myers Squibb Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Total Revenue (USD Million) (2017-2018)
Table 51. Bristol-Myers Squibb SWOT Analysis
Table 52. Bristol-Myers Squibb Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product and Solutions
Table 53. Bristol-Myers Squibb Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Cellerant Therapeutics Corporate Information, Location and Competitors
Table 55. Cellerant Therapeutics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Major Business
Table 56. Cellerant Therapeutics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Total Revenue (USD Million) (2017-2018)
Table 57. Cellerant Therapeutics SWOT Analysis
Table 58. Cellerant Therapeutics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Product and Solutions
Table 59. Cellerant Therapeutics Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) by Players (2015-2020)
Table 61. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Share by Players (2015-2020)
Table 62. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) by Regions (2015-2020)
Table 63. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Regions (2015-2020)
Table 64. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Countries (2015-2020)
Table 65. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Countries (2015-2020)
Table 66. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) by Countries (2015-2020)
Table 67. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) by Countries (2015-2020)
Table 68. South America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Countries (2015-2020)
Table 69. South America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Countries (2015-2020)
Table 70. Middle East and Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) by Countries (2015-2020)
Table 71. Middle East and Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Countries (2015-2020)
Table 72. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) by Type (2015-2020)
Table 73. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Share by Type (2015-2020)
Table 74. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Forecast by Type (2021-2025)
Table 75. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue by Application (2015-2020)
Table 76. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Share by Application (2015-2020)
Table 77. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Forecast by Application (2021-2025)
Table 78. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Picture
Figure 2. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Therapy in 2019
Figure 3. Chemotherapy Picture
Figure 4. Radiation Therapy Picture
Figure 5. Others Picture
Figure 6. Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by End Users in 2019
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Ambulatory Surgical Centers Picture
Figure 10. Others Picture
Figure 11. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 12. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. South America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Middle East and Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Share by Players in 2019
Figure 19. Global Top 5 Players Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share in 2019
Figure 20. Global Top 10 Players Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share in 2019
Figure 21. Key Players Market Share Trend
Figure 22. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 23. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Regions (2015-2020)
Figure 24. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Regions in 2018
Figure 25. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 26. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 27. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 28. South America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 29. Middle East and Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 30. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Countries (2015-2020)
Figure 31. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Countries in 2019
Figure 32. USA Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 33. Canada Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 34. Mexico Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 35. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Countries (2015-2020)
Figure 36. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Countries in 2019
Figure 37. Germany Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 38. UK Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 39. France Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 40. Russia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 41. Italy Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Countries (2015-2020)
Figure 43. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Countries in 2019
Figure 44. China Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 45. Japan Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 46. Korea Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 47. India Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 48. Southeast Asia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 49. South America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Countries (2015-2020)
Figure 50. South America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Countries in 2019
Figure 51. Brazil Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 52. Argentina Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 53. Middle East and Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Countries (2015-2020)
Figure 54. Middle East and Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share by Countries in 2019
Figure 55. Saudi Arabia Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 56. UAE Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 57. Egypt Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 58. South Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue and Growth Rate (2015-2020)
Figure 59. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Share by Type (2015-2020)
Figure 60. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Share by Type in 2019
Figure 61. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share Forecast by Type (2021-2025)
Figure 62. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 63. Global Radiation Therapy Revenue Growth Rate (2015-2020)
Figure 64. Global Others Revenue Growth Rate (2015-2020)
Figure 65. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Share by Application (2015-2020)
Figure 66. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Share by Application in 2019
Figure 67. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Market Share Forecast by Application (2021-2025)
Figure 68. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 69. Global Clinics Revenue Growth Rate (2015-2020)
Figure 70. Global Ambulatory Surgical Centers Revenue Growth Rate (2015-2020)
Figure 71. Global Others Revenue Growth Rate (2015-2020)
Figure 72. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 73. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 74. Global Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 75. North America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Forecast (2021-2025)
Figure 76. Europe Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Forecast (2021-2025)
Figure 77. Asia-Pacific Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Forecast (2021-2025)
Figure 78. South America Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Forecast (2021-2025)
Figure 79. Middle East and Africa Angioimmunoblastic T-Cell Lymphoma (AILT) Treatment Revenue Market Forecast (2021-2025)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
皮膚B細胞リンパ腫治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Cutaneous B-Cell Lymphoma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain…- B細胞性非ホジキンリンパ腫（NHL）治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The B-Cell Non-Hodgkin's Lymphoma (NHL) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, v…
- 末梢T細胞リンパ腫（PTCL）治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Peripheral T-Cell Lymphoma (PTCL) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, val…
- 皮膚T細胞リンパ腫（CTCL）治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Cutaneous T-Cell Lymphoma (CTCL) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, valu…
- T細胞リンパ腫治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The T-Cell Lymphoma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizat…